Phase II Study of Continuous Daily Sunitinib Dosing in Patients with Previously Treated Advanced Non-small Cell Lung Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2009 Oct 15

PMID 19826424

Citations 52

Authors

S Novello

G V Scagliotti

R Rosell

M A Socinski

J Brahmer

J Atkins

C Pallares

R Burgess

L Tye

P Selaru

E Wang

R Chao

R Govindan

Affiliations

Soon will be listed here.

Abstract

Background: Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC).

Methods: We examined the activity of sunitinib on a continuous daily dosing (CDD) schedule in an open-label, multicentre phase II study in patients with previously treated, advanced NSCLC. Patients > or =18 years with stage IIIB/IV NSCLC after failure with platinum-based chemotherapy, received sunitinib 37.5 mg per day. The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), 1-year survival rate, and safety.

Results: Of 47 patients receiving sunitinib, one patient achieved a confirmed partial response (ORR 2.1% (95% confidence interval (CI) 0.1, 11.3)) and 11 (23.4%) had stable disease (SD) > or =8 weeks. Five patients had SD>6 months. Median PFS was 11.9 weeks (95% CI 8.6, 14.1) and median OS was 37.1 weeks (95% CI 31.1, 69.7). The 1-year survival probability was 38.4% (95% CI 24.2, 52.5). Treatment was generally well tolerated.

Conclusions: The safety profile and time-to-event analyses, albeit relatively low response rate of 2%, suggest single-agent sunitinib on a CDD schedule may be a potential therapeutic agent for patients with advanced, refractory NSCLC.

Citing Articles

Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer.

Palumbo G, Esposito G, Carillio G, Manzo A, Montanino A, Sforza V Explor Target Antitumor Ther. 2022; 1(2):117-130.

PMID: 36046069 PMC: 9400697. DOI: 10.37349/etat.2020.00008.

Acquired tumor cell resistance to sunitinib by increased invasion and epithelial-mesenchymal transition in LL/2 murine lung cancer.

Du Y, Liu J, Tang J, Ge J, Chen Y, Cheng K Oncotarget. 2017; 8(40):68270-68279.

PMID: 28978115 PMC: 5620255. DOI: 10.18632/oncotarget.19295.

Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence.

Rothschild S Lung Cancer (Auckl). 2017; 5:51-57.

PMID: 28210142 PMC: 5217508. DOI: 10.2147/LCTT.S49490.

Synthesis and Antitumor Activity of 5-Bromo-7-azaindolin-2-one Derivatives Containing a 2,4-Dimethyl-1H-pyrrole-3-carboxamide Moiety.

Zhang J, Shen W, Li X, Chai Y, Li S, Lv K Molecules. 2016; 21(12).

PMID: 27929442 PMC: 6274105. DOI: 10.3390/molecules21121674.

Novel compounds in the treatment of lung cancer: current and developing therapeutic agents.

Bao R, Chan P J Exp Pharmacol. 2016; 3:21-34.

PMID: 27186107 PMC: 4863377. DOI: 10.2147/JEP.S7804.

References

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

Motzer R, Michaelson M, Rosenberg J, Bukowski R, Curti B, George D . Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007; 178(5):1883-7. DOI: 10.1016/j.juro.2007.07.030. View

Shikada Y, Yonemitsu Y, Koga T, Onimaru M, Nakano T, Okano S . Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res. 2005; 65(16):7241-8. DOI: 10.1158/0008-5472.CAN-04-4171. View

Burstein H, Elias A, Rugo H, Cobleigh M, Wolff A, Eisenberg P . Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008; 26(11):1810-6. DOI: 10.1200/JCO.2007.14.5375. View

Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin C, Hellberg C . Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer. 2007; 121(12):2606-14. DOI: 10.1002/ijc.22999. View

Murray L, Abrams T, Long K, Ngai T, Olson L, Hong W . SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2004; 20(8):757-66. DOI: 10.1023/b:clin.0000006873.65590.68. View

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V . Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010; 21(9):1804-1809. PMC: 2924992. DOI: 10.1093/annonc/mdq020. View

Yuan A, Yu C, Kuo S, Chen W, Lin F, Luh K . Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol. 2001; 19(2):432-41. DOI: 10.1200/JCO.2001.19.2.432. View

Ofarrell A, Abrams T, Yuen H, Ngai T, Louie S, Yee K . SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003; 101(9):3597-605. DOI: 10.1182/blood-2002-07-2307. View

10.

Koukourakis M, Giatromanolaki A, OByrne K, Comley M, Whitehouse R, Talbot D . Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br J Cancer. 1997; 75(4):477-81. PMC: 2063312. DOI: 10.1038/bjc.1997.83. View

11.

Motzer R, Rini B, Bukowski R, Curti B, George D, Hudes G . Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295(21):2516-24. DOI: 10.1001/jama.295.21.2516. View

12.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

13.

George S, Blay J, Casali P, Le Cesne A, STEPHENSON P, DePrimo S . Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009; 45(11):1959-68. DOI: 10.1016/j.ejca.2009.02.011. View

14.

Kim D, Jo Y, Jung H, Chung H, Song J, Park K . An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab. 2006; 91(10):4070-6. DOI: 10.1210/jc.2005-2845. View

15.

Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder S . Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol. 2009; 27(25):4068-75. DOI: 10.1200/JCO.2008.20.5476. View

16.

Hanna N, Shepherd F, Fossella F, Pereira J, de Marinis F, von Pawel J . Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22(9):1589-97. DOI: 10.1200/JCO.2004.08.163. View

17.

Abrams T, Lee L, Murray L, Pryer N, Cherrington J . SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003; 2(5):471-8. View

18.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

19.

Potapova O, Laird A, Nannini M, Barone A, Li G, Moss K . Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther. 2006; 5(5):1280-9. DOI: 10.1158/1535-7163.MCT-03-0156. View

20.

Shepherd F, Dancey J, Ramlau R, Mattson K, Gralla R, ORourke M . Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18(10):2095-103. DOI: 10.1200/JCO.2000.18.10.2095. View